0L49 Stock Overview
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SCYNEXIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.40 |
| 52 Week High | US$3.86 |
| 52 Week Low | US$1.40 |
| Beta | 1.57 |
| 1 Month Change | -6.04% |
| 3 Month Change | -29.58% |
| 1 Year Change | -55.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0L49 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -13.8% | 0.2% | -1.4% |
| 1Y | -55.7% | -5.3% | -2.4% |
Return vs Industry: 0L49 underperformed the UK Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: 0L49 underperformed the UK Market which returned -1% over the past year.
Price Volatility
| 0L49 volatility | |
|---|---|
| 0L49 Average Weekly Movement | 11.0% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0L49's share price has been volatile over the past 3 months.
Volatility Over Time: 0L49's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 29 | David Angulo | www.scynexis.com |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
SCYNEXIS, Inc. Fundamentals Summary
| 0L49 fundamental statistics | |
|---|---|
| Market cap | US$53.23m |
| Earnings (TTM) | US$67.04m |
| Revenue (TTM) | US$140.14m |
0.8x
P/E Ratio0.4x
P/S RatioIs 0L49 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0L49 income statement (TTM) | |
|---|---|
| Revenue | US$140.14m |
| Cost of Revenue | US$15.62m |
| Gross Profit | US$124.52m |
| Other Expenses | US$57.48m |
| Earnings | US$67.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.78 |
| Gross Margin | 88.85% |
| Net Profit Margin | 47.84% |
| Debt/Equity Ratio | 16.4% |
How did 0L49 perform over the long term?
See historical performance and comparison